Written Comment Request- Dupixent and Skyrizi

Logo for the Maryland Prescription Drug Affordability Board with the Maryland flag design above the organizations name on a maroon background.

Home › Archive for Prescription Drugs In accordance with COMAR 14.01.01.05B(4), the Prescription Drug Affordability Board requests public written comment for the cost review study process on: Dupixent (dupilumab) Drug Brand Name: Dupixent Active Moiety or Active Ingredient: dupilumab Application Number: BLA761055 NDC 11s in the Cost Review Study Process AND Skyrizi (risankizumab) Drug Brand…

Read More